Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K1EG
|
|||
| Former ID |
DIB007536
|
|||
| Drug Name |
QAV-680
|
|||
| Indication | Allergic rhinitis [ICD-11: CA08.0] | Phase 2 | [1] | |
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H18N2O4S
|
|||
| Canonical SMILES |
CC1=C(C2=C(N1CC3=CC=C(C=C3)S(=O)(=O)C)N=CC=C2)CC(=O)O
|
|||
| InChI |
1S/C18H18N2O4S/c1-12-16(10-17(21)22)15-4-3-9-19-18(15)20(12)11-13-5-7-14(8-6-13)25(2,23)24/h3-9H,10-11H2,1-2H3,(H,21,22)
|
|||
| InChIKey |
YOPFAMROKXHVCQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 872365-16-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin D2 receptor 2 (PTGDR2) | Target Info | Antagonist | [2] |
| Reactome | Prostanoid ligand receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01103037) Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma. U.S. National Institutes of Health. | |||
| REF 2 | Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.